Posted by Michael Wonder on 17 Aug 2021
PHARMAC to fund new cardiovascular medicine with amended Special Authority criteria
17 August 2021 - Pharmac has approved funding for a new medicine with substantial health benefits for around 75,000 New Zealanders at high-risk of cardiovascular disease.
People with at high-risk of cardiovascular disease, who meet the funding criteria, will be able to access funded rosuvastatin from 1 December 2021.
